First and foremost, the accumulated data should provide physicians with the rare confidence to do less rather than more, a finding that also has become apparent with anticoagulation therapy.
The clinical goal, however, should be to avoid thromboinflammation and hospitalization in the first place, an objective largely achievable through aggressive vaccination.
At 28 days, mortality was 17% in both the aspirin and usual care groups rate ratio, 0.
In this subsequent adaptive pooled analysis, the median number of organ support—free days was 7 in both the antiplatelet and control groups adjusted odds ratio for the effect of antiplatelet therapy compared with control, 1.
Identifying the characteristics of moderately ill patients who might benefit from therapeutic-dose heparin is currently being investigated.
Not all submitted comments are published.